NDT Advance Access published online on December 7, 2004
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh606
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medical Clinic III, Department of Cardiology, Nephrology, Hypertension and Renal Failure, Eberhard-Karls-University, D-72076 Tübingen, Germany; These authors contributed equally to this work
* To whom correspondence should be addressed. Background. Cardiovascular disease is the most important cause of death in patients with end-stage renal disease. In uraemia, the renin-angiotensin-aldosterone and endothelin (ET) systems are activated. It is not known whether inhibition of these systems attenuates the proliferation of isolated smooth muscle cells of uraemic rats. Methods. Subtotally nephrectomized (SNX) rats were treated with an ETA receptor antagonist, an ETAB receptor antagonist, the angiotensin type 1 (AT1) receptor antagonist losartan (all 10 mg/kg body weight/day) or the angiotensin-converting enzyme (ACE) inhibitor trandolapril (0.1 mg/kg body weight/day) or received no medication (SNX) for 12 weeks. Then, aortal smooth muscle cells (SMCs) were isolated and cultivated. After incubation of SMCs with different growth factors (5-7 days), proliferation was measured using a bromodeoxyuridine enzyme-linked immunosorbent assay (BrdU ELISA). Results. Higher maximum levels of proliferation were found in SMCs from untreated SNX rats than in SMCs from control animals [platelet-derived growth factor-BB (PDGF-BB) 486.60±8.27 vs 346.74±4.60%, basic fibroblast growth factor (bFGF) 176.68±6.50 vs 123.71±1.49%, tumour necrosis factor- Conclusions. Treatment of SNX rats with ET receptor antagonists or losartan reduced growth factor-induced SMC proliferation in vitro. However, further investigations with uraemic patients have to clarify whether angiotensin or ET receptor antagonists inhibit the development of atherosclerosis.
Received June 9, 2004
Accepted October 20, 2004
Original Articles
Influence of growth factors on the proliferation of vascular smooth muscle cells isolated from subtotally nephrectomized rats after endothelin or angiotensin II antagonism
2 Section of Radiobiology and Molecular Environmental Research, Department of Radiotherapy, Eberhard-Karls-University, D-72076 Tübingen, Germany
3 Medical Clinic III, Department of Cardiology, Nephrology, Hypertension and Renal Failure, Eberhard-Karls-University, D-72076 Tübingen, Germany
4 Medical Clinic III, Department of Cardiology, Nephrology, Hypertension and Renal Failure, Eberhard-Karls-University, D-72076 Tübingen, Germany; Department of General Neurology, Hertie Institute for Clinical Brain Research, Eberhard-Karls-University, D-72076 Tübingen, Germany
Bernhard R. Brehm, E-mail: bernhard.brehm{at}onlinehome.de
Abstract 
(TNF-) 153.38±10.16 vs 122.27±1.41%]. Treatment with ET receptor antagonists or losartan attenuated growth factor-stimulated proliferation (PDGF-BB: ETA receptor antagonist, 135.71±1.08%; ETAB receptor antagonist, 122.72±0.58%; losartan: 103.69±1.83%, n = 8). SMCs from trandolapril-treated rats showed an increased response (PDGF-BB 663.48±7.00%, n = 8).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. T. Chan, F. Lovren, Y. Pan, and S. Verma Nocturnal haemodialysis is associated with improved vascular smooth muscle cell biology Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3867 - 3871. [Abstract] [Full Text] [PDF]
|
|